Literature DB >> 31098204

Delivering person-centred care in long-term conditions.

Simon Eaton1.   

Abstract

The components of supporting people with long-term conditions, and the incumbent skills and resources required, are increasingly well understood. However, more coherent and systematic approaches to delivery across care pathways are -required. In the setting of intermittent, discrete decisions about healthcare, the concept of shared decision making will apply. Support for self-management describes efforts to help people in living day to day with their condition(s). Care planning is relevant to proactively planning cycles of care and increasing involvement in care. The underpinning principles require a different mindset for clinicians and support for people to develop the knowledge, skills and confidence to engage and participate in their health more effectively. Achieving this could provide the holy grail of delivering high-quality care at a population level, which is consistently centred around what is important to each individual person and what they want to achieve.

Entities:  

Keywords:  Long-term conditions; biopsychosocial; care planning; patient activation; person-centred care; shared decision making; support for self-management; ­patient involvement

Year:  2016        PMID: 31098204      PMCID: PMC6465836          DOI: 10.7861/futurehosp.3-2-128

Source DB:  PubMed          Journal:  Future Hosp J        ISSN: 2055-3323


  2 in total

Review 1.  Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.

Authors:  Rieke Alten; Yoorim An; Dong-Hyeon Kim; SangWook Yoon; Laurent Peyrin-Biroulet
Journal:  Clin Drug Investig       Date:  2022-06-03       Impact factor: 2.859

2.  Rehabilitation Workforce Challenges to Implement Person-Centered Care.

Authors:  Júlio Belo Fernandes; Diana Vareta; Sónia Fernandes; Ana Silva Almeida; Dina Peças; Noélia Ferreira; Liliana Roldão
Journal:  Int J Environ Res Public Health       Date:  2022-03-08       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.